Mogroside V Alleviates Lipopolysaccharide-Induced Neuroinflammation via Inhibition of TLR4-MyD88 and Activation of AKT/AMPK-Nrf2 Signaling Pathway

Figure 7

Mog can upregulate AKT/AMPK expression in BV-2 cells. (a) BV-2 cells were pretreated with Mog (0, 3.125, 6.25, 12.5, and 50 μM) for 2 h, and whole cell lysates were subjected to western blotting analysis with AKT, p-AKT, AMPK, and p-AMPK. (d) BV-2 cells were treated with LPS (1 μg/mL) for 1 h after incubation with various concentrations (0, 6.25, 12.5, and 25 μM) of Mog for 2 h. Total protein extracts from different treatment for BV-2 cells were prepared for detecting AKT, p-AKT, AMPK, and p-AMPK. (b-c and e-f) Protein samples were analyzed by western blot with specific antibodies as described. Similar results were obtained from three independent experiments. The values presented are the means ± SEM.  < 0.05 and  < 0.01 versus control group; ^# < 0.05 and ^## < 0.01 versus LPS group.

(a)

(b)

(c)

(d)

(e)

(f)